Suscribirse

Preterm birth reduces the incidence of atopy in adulthood - 11/08/11

Doi : 10.1016/j.jaci.2010.12.1107 
Mirjami Siltanen, MD, PhD a, b, Karoliina Wehkalampi, MD, PhD a, c, Petteri Hovi, MD a, c, Johan G. Eriksson, MD, PhD a, d, e, f, g, Sonja Strang-Karlsson, MD a, c, Anna-Liisa Järvenpää, MD, PhD c, Sture Andersson, MD, PhD c, Eero Kajantie, MD, PhD a, c,
a Division of Welfare and Health Promotion, Department of Chronic Disease Prevention, Diabetes Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland 
b Hyvinkää Hospital, Hyvinkää, Finland 
c Hospital for Children and Adolescents, Helsinki University Hospital, Helsinki, Finland 
f Unit of General Practice, Helsinki University Central Hospital, Helsinki, Finland 
d Department of General Practice and Primary Health Care, University of Helsinki, Helsinki, Finland 
e Vasa Central Hospital, Vasa, Finland 
g Folkhälsan Research Centre, Helsinki, Finland 

Reprint requests: Eero Kajantie, MD, PhD, National Institute for Health and Welfare, Mannerheimintie 164, PO Box 30, FIN-00271 Helsinki, Finland.

Abstract

Background

Immunologic pathways are primed in early life. Preterm birth can influence this process and thereby affect whether a person will have atopy later in life. Previous studies on the effects of preterm birth on atopy in adulthood have been inconclusive and limited to children or subjects born moderately preterm.

Objective

Our aim was to compare the incidence of atopy among young adults who were born preterm and at very low birth weight (≤1500 g) with that of term-born young adults (control subjects).

Methods

The study comprised 166 adults who were born preterm and at very low birth weight and 172 control subjects, all of whom were from the Helsinki Study of Very Low Birth Weight Adults. We assessed atopic predisposition at ages 18 to 27 years using skin prick tests for 6 common aeroallergens and measurements of serum concentrations of total IgE and 3 types of allergen-specific (cat, birch, and timothy) IgE. We asked the subjects whether they had been given a diagnosis of asthma or allergic rhinitis or had atopic eczema and analyzed data by using logistic or linear regression, adjusting for potential confounding factors.

Results

The risk for having at least 1 positive reaction on a skin prick test was reduced (adjusted odds ratio, 0.43; 95% CI, 0.23-0.79, P = .007), and the concentration of cat-specific IgE was less (25% less; 95% CI, 43% to 2.3% less; P = .033) in sera from very-low-birth-weight subjects compared with that seen in sera from control subjects. Within the very-low-birth-weight group, those born at an earlier gestational age were less likely to have positive skin prick test reactions (adjusted odds ratio for 1 week, 0.82; 95% CI, 0.68-0.98, P = .029) and less likely to have high levels of allergen-specific IgE. Cumulative incidences of atopic disease were similar between adults of very low birth weight and control subjects.

Conclusions

Young adults born prematurely and at very low birth weight have a lower incidence of atopy than adults who were born full term. This finding supports the hypothesis that the risk for atopy is determined during early stages of development.

El texto completo de este artículo está disponible en PDF.

Key words : Atopy, allergy, skin prick test, total IgE, allergen-specific IgE, prematurity, very low birth weight, gestational age

Abbreviation used : OR


Esquema


 The Helsinki Study of Very Low Birth Weight Adults has received grant support from the following sources: the Finnish Foundation for Pediatric Research (E.K., K.W., M.S., P.H., and S.A.), Finska Läkaresällskapet (J.G.E. and S.A.), the Finnish Special Governmental Subsidy for Health Sciences (J.G.E. and S.A.), the Academy of Finland (K.W., J.G.E., S.A., and E.K.), the Biomedicum Helsinki Foundation (S.S.K.), the Emil Aaltonen Foundation, the Finnish Concordia Foundation (S.S.K.), the Finnish Medical Society Duodecim (E.K.), the Finnish National Graduate School of Clinical Investigation (S.S.K.), the Jalmari and Rauha Ahokas Foundation (E.K.), the Juho Vainio Foundation (J.G.E. and E.K.), the Novo Nordisk Foundation (J.G.E. and E.K.), the Päivikki and Sakari Sohlberg Foundation (J.G.E. and E.K.), the Pediatric Graduate School (P.H. and S.S.K.), the Clinical Graduate School in Paediatrics and Obstetrics/Gynaecology (P.H.), the University of Helsinki (J.G.E.), the Perklén Foundation (S.S.K.), the Research Foundation for the Orion Corporation (P.H.), the Signe and Ane Gyllenberg Foundation (J.G.E. and E.K.), the Sigrid Juselius Foundation (S.A. and E.K.), the Waldemar von Frenckell Foundation (S.S.K.), Vasa Nation (S.S.K.), Wiipurilainen Osakunta (E.K.) at Helsinki University, the Wilhelm and Else Stockmann Foundation (S.S.K.), and the Yrjö Jahnsson Foundation (P.H., J.G.E., and E.K.).
 Disclosure of potential conflict of interest: M. Siltanen has received research support from the Finnish Foundation of Pediatric Research. The rest of the authors have declared that they have no conflict of interest.


© 2011  American Academy of Allergy, Asthma & Immunology. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 127 - N° 4

P. 935-942 - avril 2011 Regresar al número
Artículo precedente Artículo precedente
  • Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis
  • Fuad M. Baroody, David Brown, Laura Gavanescu, Marcy DeTineo, Robert M. Naclerio
| Artículo siguiente Artículo siguiente
  • Histamine receptor H1 signaling on dendritic cells plays a key role in the IFN-γ/IL-17 balance in T cell–mediated skin inflammation
  • Béatrice Vanbervliet, Mübeccel Akdis, Marc Vocanson, Aurore Rozières, Josette Benetière, Paul Rouzaire, Cezmi A. Akdis, Jean-François Nicolas, Ana Hennino

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.